WCG Wealth Advisors LLC Buys 22,434 Shares of Johnson & Johnson $JNJ

WCG Wealth Advisors LLC boosted its stake in Johnson & Johnson (NYSE:JNJ) by 187.7% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 34,389 shares of the company’s stock after purchasing an additional 22,434 shares during the quarter. WCG Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $7,117,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Blueline Advisors LLC purchased a new stake in Johnson & Johnson in the 4th quarter worth $25,000. Cresta Advisors Ltd. purchased a new stake in Johnson & Johnson in the 4th quarter worth $26,000. Abich Financial Wealth Management LLC purchased a new stake in Johnson & Johnson in the 3rd quarter worth $26,000. DecisionPoint Financial LLC lifted its stake in Johnson & Johnson by 104.2% in the 4th quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock worth $30,000 after purchasing an additional 75 shares in the last quarter. Finally, Bay Harbor Wealth Management LLC lifted its stake in Johnson & Johnson by 49.0% in the 4th quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock worth $31,000 after purchasing an additional 49 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson reported encouraging Phase 2 results for nipocalimab in lupus, meeting the primary endpoint and showing sustained disease activity reduction through 52 weeks. Article Title
• Positive Sentiment: New Sjögren’s disease data further reinforced nipocalimab’s ability to reduce autoantibodies and showed stronger response rates in patients with higher disease burden. Article Title
• Neutral Sentiment: Johnson & Johnson is drawing extra investor attention, likely reflecting renewed focus on the stock after the recent pipeline updates and broader interest in defensive healthcare names. Article Title
• Neutral Sentiment: Commentary on Johnson & Johnson as a potential high-growth dividend stock may be supporting the company’s income-investor appeal, but it does not appear to reflect a new operating development. Article Title
• Neutral Sentiment: Scotiabank reiterated a Buy rating on Johnson & Johnson, which can help reinforce confidence in the stock among investors. Article Title

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $223.60 on Thursday. Johnson & Johnson has a 1 year low of $149.04 and a 1 year high of $251.71. The company’s 50 day simple moving average is $232.25 and its 200-day simple moving average is $225.69. The company has a market capitalization of $538.25 billion, a price-to-earnings ratio of 25.85, a price-to-earnings-growth ratio of 2.18 and a beta of 0.26. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The firm had revenue of $24.06 billion for the quarter, compared to the consensus estimate of $23.60 billion. During the same period in the prior year, the firm earned $2.77 EPS. The firm’s revenue for the quarter was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, equities research analysts expect that Johnson & Johnson will post 11.57 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th will be issued a $1.34 dividend. This represents a $5.36 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Tuesday, May 26th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s dividend payout ratio (DPR) is currently 61.97%.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of research analyst reports. Argus upped their target price on shares of Johnson & Johnson from $240.00 to $275.00 and gave the stock a “buy” rating in a research note on Thursday, April 16th. Wells Fargo & Company increased their price objective on shares of Johnson & Johnson from $240.00 to $263.00 and gave the company an “overweight” rating in a research note on Wednesday, April 15th. JPMorgan Chase & Co. increased their price objective on shares of Johnson & Johnson from $250.00 to $260.00 and gave the company a “neutral” rating in a research note on Wednesday, April 15th. Raymond James Financial increased their target price on shares of Johnson & Johnson from $237.00 to $258.00 and gave the company an “outperform” rating in a research report on Wednesday, April 15th. Finally, The Goldman Sachs Group raised their price target on shares of Johnson & Johnson from $265.00 to $275.00 and gave the stock a “buy” rating in a report on Wednesday, April 15th. Twenty investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $253.04.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.